Urinary tract infections in children: an overview of diagnosis and management

Jonathan Kaufman,1,2,3 Meredith Temple-Smith,3 Lena Sanci3

ABSTRACT
Urinary tract infections (UTIs) are a common and potentially serious bacterial infection of childhood. History and examination findings can be non-specific, so a urine sample is required to diagnose UTI. Sample collection in young precontinent children can be challenging. Bedside dipstick tests are useful for screening, but urine culture is required for diagnostic confirmation. Antibiotic therapy must be guided by local guidelines due to increasing antibiotic resistance. Duration of therapy and indications for imaging remain controversial topics and guidelines lack consensus. This article presents an overview of paediatric UTI diagnosis and management, with highlights of recent advances and evidence updates.

BACKGROUND
Prevalence and epidemiology
Urinary tract infection (UTI) is one of the most common bacterial infections of childhood. Among febrile infants, unwell children in general practice and older children with urinary symptoms, 6%–8% will have a UTI.1 2 Prevalence varies with age, peaking in young infants, toddlers and older adolescents. UTI is more common in female and uncircumcised male infants, understandable given bacterial skin flora concentration under the nappy in infancy, shorter female urethral distance and foreskin surface area in uncircumcised males. During toddler years, toilet training can lead to volitional holding and bladder stasis, increasing reservoir and more time to establish infection. Toddler voiding flushes bacteria out of the urinary system.3 Impaired urine flow leads to urinary stasis, giving bacteria an increased reservoir and more time to establish infection. Causes of disordered voiding can be structural (urogenital anomalies) or functional (neurogenic bladder, constipation and behavioural withholding). Altered immune function can increase the risk of uncommon viral and fungal causes of UTI.

Conditions that impair urinary flow increase susceptibility to UTI. Voiding flushes bacteria out of the urinary system.3 Impaired urine flow leads to urinary stasis, giving bacteria an increased reservoir and more time to establish infection. Causes of disordered voiding can be structural (urogenital anomalies) or functional (neurogenic bladder, constipation and behavioural withholding). Altered immune function can increase the risk of uncommon viral and fungal causes of UTI.4

Over 30% of children with UTI will have recurrent UTI.4 Common risk factors for recurrence include vesicoureteric reflux (VUR) and bladder–bowel dysfunction.4 Older non-continent children (eg, developmental delay) also have more recurrent UTIs. Being such a common infection, UTI contributes a significant economic burden to the healthcare system. Use of evidence-based management has the potential for significant cost savings.5

Aetiology
Most paediatric UTIs are caused by Gram negative coliform bacteria arising from faecal flora colonising the perineum, which enter and ascend the urinary tract.3 Escherichia coli (E.coli) is the most common uropathogen, responsible for approximately 80% of paediatric UTIs.6 Uropathogenic E.coli strains possess specific properties, such as fimbriae to attach to the uroepithelial cell surface, to allow them to overcome host defences (figure 1).3 Other common uropathogens include Klebsiella, Proteus, Enterobacter and Enterococcus species.6 7

Upper versus lower tract UTI
UTI can be categorised anatomically into upper tract and lower tract infection.8 Upper tract UTI involves infection and inflammation in the kidneys (pyelonephritis) and ureters (figure 2). This typically leads to abdominal pain and loin tenderness, with systemic features such as fever, anorexia, vomiting, lethargy and malaise. Lower tract UTI involves infection within the bladder (cystitis) and urethra, with localised symptoms such as lower abdominal or suprapubic pain, dysuria, urinary frequency and urgency. Older children may present with signs and symptoms suggesting the site of infection. In younger patients, these classical signs are often absent, and differentiating between upper and lower UTI is less obvious.

Morbidity
Acute UTI encompasses the full spectrum of severity from mild dysuria in an otherwise well child to life-threatening urosepsis. While serious infections are less common, they can and do occur, particularly in neonates.9 Since

1Department of Paediatrics, Western Health, Sunshine Hospital, St Albans, Victoria, Australia
2Health Services Research Group, Murdoch Children’s Research Institute, Parkville, Victoria, Australia
3Department of General Practice, Faculty of Medicine Dentistry & Health Sciences, The University of Melbourne, Melbourne, Victoria, Australia

Correspondence to Dr Jonathan Kaufman; jkaufman@unimelb.edu.au
Bacteraeemia can then lead to urosepsis. Meningitis can also occur with haematogenous spread to the cerebrospinal fluid (CSF). The risk of coexisting meningitis and UTI is 1% in the neonatal period, suggesting a low threshold to perform lumbar puncture in this age group. Beyond 1 month, the risk is smaller. Typical empirical UTI antibiotics have poor CSF penetration and inadequate duration to treat bacterial meningitis.

Long-term morbidity follows renal injury and scarring from upper tract UTI. Around 15% of children with first UTI who have follow-up scanning will have evidence of renal scarring. This scarring would be clinically important if it led to renal dysfunction, hypertension and chronic kidney disease (CKD). Historical thinking suggested these sequelae were common, leading to aggressive imaging guidelines to identify children at risk of CKD. Recent data suggest the risks are much lower. A 2011 systematic review of 1576 cases found no cases where childhood UTI was the main cause of subsequent CKD. Of a further 366 local CKD patients in the same study, 13 (3%) had a history of UTI in childhood but all had renal abnormalities evident on renal ultrasound, and recurrent UTI was possibly the cause of CKD in only one case (0.3%). Therefore, in the absence of structural renal anomalies or recurrent UTI, the risk of CKD appears minimal. Debate about the significance of post-UTI renal scarring continues.

**DIAGNOSIS**

Clinical features of paediatric UTI are remarkably non-specific, especially in younger children. Diagnosis can be challenging but is important to consider, especially for infants with fever without focus.

**History**

Younger preverbal children cannot report symptoms such as dysuria or abdominal pain. Parents often notice non-specific signs, such as lethargy, irritability, poor feeding and vomiting. These overlap with many common and benign viral infections, as well as serious bacterial infections. Fever is often present, may be the only feature present or the child may be afebrile. Malodorous or discoloured urine may be obscured in nappy-wearing children. Older children may report localising symptoms such as dysuria or flank pain.

**Examination**

Children with UTI may appear very well or very unwell. Fever, abdominal tenderness and dehydration may be identified. Localising signs are more likely in older children. As clinical diagnosis is unreliable, a urine sample is required for further evaluation.

**Urine sample collection: continent children**

Continent children can void on request to provide a midstream urine (MSU) sample into a sterile collection jar. The first voided urine flushes skin flora away from

---

Figure 1  *Escherichia coli* with fimbriae. Image courtesy of Dennis Kunkel Microscopy, Science Photo Library.

Figure 2  Urogenital system: upper versus lower tract UTI. Image courtesy of Dr Jonathan Kaufman. UTI, urinary tract infection.
the urethral orifice, before sample collection from the middle of the urinary stream. Cleaning with soap and water before MSU further reduces contamination.14

Urine sample collection: precontinent children

Young children in Western society generally do not achieve urinary continence until 2–3 years old, so other collection methods are required for precontinent children. Non-invasive methods involve waiting for spontaneous urine voiding, then opportunistic collection with a nappy pad, bag, or ‘clean catch’ of the urine stream. These methods seem convenient and practical. However, pads and bags have high rates of contamination up to 50%–60%,2 15 understandable given their close contact with skin under the nappy area. Pad and bag samples can be useful for dipstick screening but are unreliable for culture. Cotton wool ball collection is specifically discouraged.16 Clean catch has the lowest contamination of all non-invasive methods at around 25%,17 but attempts can be time-consuming or unsuccessful. Simple voiding stimulation methods such as the Quick-Wee technique can increase the speed and success of clean catch.18 19

Invasive methods extract urine directly from the bladder by urethral catheterisation or suprapubic needle aspiration (SPA). These methods are effective but require expertise and equipment to perform and are painful and distressing for the child. Contamination from catheter and SPA is low, at 10% and 1% respectively,17 so these methods are more reliable for culture and diagnosis.

The optimal collection method remains controversial (table 1). Each method has advantages and limitations, and guidelines have different recommendations.20 In the UK, where general practitioners provide primary care, guidelines recommend clean catch or other non-invasive methods if clean catch is not possible, and catheter or SPA only if non-invasive methods are not possible or practical.16 In the USA, where paediatricians often provide primary care, guidelines recommend the opposite, that catheter or SPA is required to confirm UTI, though convenient methods such as urine bags can be used for screening.21 Most international guidelines recommend catheter or SPA as the gold standard, include clean catch as an acceptable collection method, and specifically discourage the use of bag samples for culture.22–24 A two-step process using initial bag screening and catheter confirmation of positive screens can reduce the rate of invasive procedures.25

Who needs evaluation for UTI

Clinical diagnosis of UTI is unreliable, so many children with fever or symptoms of UTI need a urine sample to exclude or make the diagnosis. Urine samples should be collected before starting antibiotics, but therapy should not be delayed in the septic child.

Children with localising signs or suspected UTI need a urine sample to confirm the diagnosis.16

Children with fever without focus, particularly neonates and infants, need a urine sample to evaluate potential

<table>
<thead>
<tr>
<th>Table 1</th>
<th>Urine collection methods for precontinent children</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Non-invasive methods</strong></td>
<td><strong>Invasive methods</strong></td>
</tr>
<tr>
<td><strong>Nappy pad</strong></td>
<td><strong>Urine bag</strong></td>
</tr>
<tr>
<td></td>
<td>Useful for dipstick screening.</td>
</tr>
<tr>
<td><strong>Contamination rate</strong></td>
<td>&gt;60%2</td>
</tr>
<tr>
<td><strong>Cost per definitive sample in an emergency department setting</strong></td>
<td>–</td>
</tr>
</tbody>
</table>

SPA, suprapubic needle aspiration.
UTI. Outside early infancy and if the child is not unwell, it may be reasonable to wait 24 hours for collection to see if an alternative focus emerges.\textsuperscript{16}

Children with an alternative focus of illness generally do not need a urine sample.\textsuperscript{16} Exceptions are septic infants, children with predisposing conditions (eg, renal anomalies), children at risk of complications (eg, single kidney) and febrile illness not following the expected clinical course.

**Screening – dipstick and microscopy**

Urine dipsticks are a quick, inexpensive bedside screening tool. Chemical reagent strips change colour in the presence of leucocyte esterase (an enzyme present in leucocytes) and nitrites, which may arise from UTI.\textsuperscript{26} Leucocytes generally appear in the urine in response to UTI. However, sterile pyuria can occur with other infections. *Enterococcus, Klebsiella* and *Pseudomonas* species are also less likely to produce pyuria than *E.coli* in children with symptomatic UTI.\textsuperscript{27} Most uropathogens convert dietary nitrates into urinary nitrites. However, not all do, including *Enterococcus* and *Klebsiella* species.\textsuperscript{28} Dipsticks are also less reliable in young infants, where frequent voiding flushes substrates out of the bladder.\textsuperscript{26}

Neither leucocytes or nitrites are fully sensitive or specific for UTI, but they are a useful screening test, particularly when used in combination. If UTI is thought unlikely, dipsticks have a good negative predictive value to exclude the diagnosis.\textsuperscript{29} In the presence of suggestive symptoms and either leucocytes or nitrites, empirical antibiotics while awaiting culture is indicated.\textsuperscript{16}

Urine microscopy also identifies leucocytes and bacteria, augmenting dipstick screening.

**Diagnosis: culture**

Laboratory culture is the gold standard for UTI diagnosis. Urine is sterile; therefore, the presence of bacteria in sufficient quantity, with concurrent evidence of active infection, suggests UTI. Urine is added to a growth medium, from which bacteria and antibiotic sensitivities are identified. Culture takes around 24 hours, then the presumptive diagnosis can be reviewed. All major UTI guidelines recommend culture is required for UTI diagnosis.\textsuperscript{16,21}

How many bacteria are needed to diagnose UTI in children? Thresholds vary between guidelines and collection methods.\textsuperscript{24,29} The commonly quoted threshold of 100 000 CFU/mL of a single organism is based on a seminal study in adult women by Kass\textsuperscript{30} from 1956. Does this threshold apply in children? American guidelines suggest 50 000 CFU/mL threshold with concurrent pyuria for SPA and catheter specimens.\textsuperscript{21} More recent evidence suggests an even lower 10 000 CFU/mL threshold would slightly increase sensitivity without reducing diagnostic specificity.\textsuperscript{29} Many guidelines suggest that any growth on SPA is abnormal,\textsuperscript{35} as SPA has negligible contamination.

Asymptomatic bacteriuria (ASB) is the presence of bacteria in the urine without active infection. ASB prevalence is estimated at 1.4%–1.9% in childhood.\textsuperscript{31,32} Bacterial growth without evidence of active infection (eg, pyuria) does not suggest UTI.

In reality, these diagnostic thresholds are not binary.\textsuperscript{16} Low colony counts on culture may represent early infection, contamination or ASB. Pyuria may occasionally be absent in early infection or immunocompromise. Screening and culture results must always be considered in the clinical context.

**Contamination**

Contamination muddies the waters when evaluating UTI. Assuming a single uropathogen causes UTI, multiple organisms suggests sample contamination. Incidental flora colonise the perigenital skin and can get flushed into the urine sample on voiding. Missed diagnosis can occur if a true uropathogen is concealed in the mix or misdiagnosis if a single contaminant dominates the culture. Contamination can be minimised by cleaning the perigenital skin before sample collection\textsuperscript{14} and avoiding touching inside the specimen jar or holding the jar against the child’s skin.

**What is on the horizon?**

Current tests for UTI lack absolute sensitivity or specificity. Urinary biomarkers such as interleukin 6 and neutrophil gelatinase-associated lipocalin have been proposed to differentiate between active infection and ASB. Real-time PCR has been proposed to identify common uropathogens such as *E.coli*.\textsuperscript{26} Further research is required to understand the clinical utility of these emerging tests.

**INITIAL MANAGEMENT**

**General**

Children with UTI require targeted antibiotics and supportive care. Most children with UTI can be managed at home with oral fluids and antibiotics. A small percentage will require admission for intravenous therapy, including very young and very unwell children, children with significant renal tract anomalies and children not responding to oral therapy.

**Antibiotic therapy**

Choice of empiric antibiotics must be guided by local guidelines, as local antimicrobial sensitivities vary significantly (table 2). The suitability of the initial agent should be reviewed once culture results are available.

Oral antibiotics are effective for the overwhelming majority of paediatric UTI. Previous Cochrane reviews suggest that short 2–4 days courses are as effective as longer 7–14 days for uncomplicated cystitis,\textsuperscript{33} while single dose therapy is less effective.\textsuperscript{34} American guidelines recommend treatment durations of 7–14 days for both cystitis and pyelonephritis.\textsuperscript{21} Canadian guidelines recommend 7–10 days,\textsuperscript{35} while National Institute for Health and
Table 2: Recent evidence, controversies and emerging evidence

**RECENT EVIDENCE**

<table>
<thead>
<tr>
<th>Method</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Urine bag collection</td>
<td>High contamination rates ~50%. Least cost-effective collection method. Use for dipstick screening but unreliable for culture.</td>
</tr>
<tr>
<td>Voiding stimulation methods</td>
<td>Improves the speed, success and cost-effectiveness of clean catch urine collection in precontinent children</td>
</tr>
<tr>
<td>Antibiotic prophylaxis</td>
<td>Not recommended after first or second UTI in otherwise healthy children. Modest effect on recurrence, does not reduce scarring and increases antibiotic resistance.</td>
</tr>
</tbody>
</table>

**CONTROVERSIES**

<table>
<thead>
<tr>
<th>Topic</th>
<th>Information</th>
</tr>
</thead>
<tbody>
<tr>
<td>What colony counts on culture represent true UTI?</td>
<td>Historical: 100,000 CFU/mL; NICE: no specific recommendation; AAP: 50,000 CFU/mL from catheter/SPA sample with pyuria; Proposed: 10,000 CFU/mL with symptoms/pyuria.</td>
</tr>
<tr>
<td>Duration of antibiotic therapy?</td>
<td>Short-course therapy for lower tract UTI (cystitis) may be as effective as longer courses; NICE: 7–10 days for pyelonephritis and 3 days for children &gt;3 months with cystitis; AAP: 7–14 days for all UTI.</td>
</tr>
<tr>
<td>Choice of antibiotic agent?</td>
<td>Must be guided by local guidelines and sensitivity patterns, as susceptibility can vary significantly between regions.</td>
</tr>
<tr>
<td>Does uncomplicated UTI predispose to risk of chronic kidney disease?</td>
<td>Children with structurally normal kidneys appear not at significant risk of long term renal morbidity.</td>
</tr>
<tr>
<td>Imaging tests following UTI: who, what and when to image?</td>
<td>Historical: aggressive imaging to identify VUR and scarring; NICE: age and risk based approach; AAP: ultrasound for all children &lt;2 years old with febrile UTI, VCUG if ultrasound is abnormal.</td>
</tr>
</tbody>
</table>

**EMERGING EVIDENCE**

<table>
<thead>
<tr>
<th>Topic</th>
<th>Information</th>
</tr>
</thead>
<tbody>
<tr>
<td>Antibiotic resistance</td>
<td>Increasing globally, highest in resource-limited settings; Increases healthcare costs.</td>
</tr>
<tr>
<td>Urinary biomarkers to differentiate between UTI and asymptomatic bacteriuria</td>
<td>For example, interleukin-6, neutrophil gelatinase-associated lipocalin: further research needed to establish clinical utility.</td>
</tr>
<tr>
<td>Point-of-care PCR to identify presence of uropathogens</td>
<td>Can identify common uropathogens but only specified targets so may miss uncommon bacterial species. Cannot differentiate between contamination, asymptomatic bacteriuria and infection.</td>
</tr>
</tbody>
</table>

National Institute for Health and Care Excellence (NICE) UK Clinical Guideline 54: UTI in under 16s: diagnosis and management 2017. American Association of Paediatrics Clinical Practice Guideline: the diagnosis and management of the initial UTI in febrile infants and young children 2–24 months of age 2016. PCR, Polymerase Chain Reaction; SPA, suprapubic needle aspiration; UTI, urinary tract infection; VCU, Voiding Cystourethrogram; VUR, vesicoureteric reflux.

Clinical Excellence (NICE) guidelines suggests 7–10 days for pyelonephritis and a shorter 3 day course for children >3 months with cystitis. Spanish guidelines mirror NICE recommendations though single-dose therapy is recommended for children aged >6 years with uncomplicated cystitis.

Younger and sicker children may require initial intravenous therapy. Many guidelines and centres recommend admission, intravenous antibiotics and consideration of septic work-up for infants <3 months. Aim to switch to oral therapy after 48 hours if there is clinical improvement.

**Antibiotic resistance**

Antibiotic resistant UTI is becoming more common globally and increases morbidity and doubles healthcare costs. The usual mechanism is through acquisition of enhanced beta-lactamase enzyme properties. Some Gram negative uropathogens can inactivate beta-lactam ring antibiotics such as penicillin and early generation cephalosporins with inherent beta-lactamase enzymes. However, some have acquired further multidrug-resistant properties through evolution of these enzymes, including the ability to hydrolyse and inactivate extended spectrum cephalosporins and carbapenem antibiotics. Such organisms are known as extended spectrum beta lactamase (ESBL) organisms. Prior antibiotic therapy and hospitalisation are risk factors for ESBL carriage, which then contributes to community carriage and transmission of resistance. Rates of resistant UTIs are particularly high in resource-limited settings, where resistance to common oral antibiotics such as ampicillin and cotrimoxazole can be as high as 97%–100%.
## Table 3  Summary of imaging recommendations from selected international guidelines for young children with UTI

<table>
<thead>
<tr>
<th>National Institute for Health and Clinical Excellence (NICE) UK[^16]</th>
<th>Recommended imaging test(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Age 0–6 months</strong></td>
<td></td>
</tr>
<tr>
<td>Uncomplicated first UTI</td>
<td>Outpatient ultrasound.</td>
</tr>
<tr>
<td>Atypical UTI</td>
<td>Inpatient ultrasound, outpatient DMSA scan and VCUG.</td>
</tr>
<tr>
<td>Recurrent UTI</td>
<td>Inpatient ultrasound, outpatient DMSA scan and VCUG.</td>
</tr>
<tr>
<td><strong>Age 6 months–3 years</strong></td>
<td></td>
</tr>
<tr>
<td>Uncomplicated first UTI</td>
<td>No imaging.</td>
</tr>
<tr>
<td>Atypical UTI</td>
<td>Inpatient ultrasound, outpatient DMSA scan.</td>
</tr>
<tr>
<td>Recurrent UTI</td>
<td>Outpatient ultrasound, outpatient DMSA scan.</td>
</tr>
<tr>
<td><strong>Age &gt;3 years</strong></td>
<td></td>
</tr>
<tr>
<td>Uncomplicated first UTI</td>
<td>No imaging.</td>
</tr>
<tr>
<td>Atypical UTI</td>
<td>Inpatient ultrasound.</td>
</tr>
<tr>
<td>Recurrent UTI</td>
<td>Outpatient ultrasound, outpatient DMSA scan.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>American Academy of Pediatrics (AAP)[^21]</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Age 0–24 months</strong></td>
<td></td>
</tr>
<tr>
<td>Any febrile UTI</td>
<td>Ultrasound.</td>
</tr>
<tr>
<td>Complex or atypical circumstances</td>
<td>VCUG.</td>
</tr>
<tr>
<td>Recurrent UTI</td>
<td>Further evaluation.</td>
</tr>
<tr>
<td><strong>Canadian Paediatric Society (CPS)[^35]</strong></td>
<td></td>
</tr>
<tr>
<td>Any febrile UTI aged &lt;2 years</td>
<td>Ultrasound.</td>
</tr>
<tr>
<td><strong>European Association of Urology/European Society for Paediatric Urology[^23]</strong></td>
<td></td>
</tr>
<tr>
<td>Any febrile UTI</td>
<td>Ultrasound.</td>
</tr>
<tr>
<td>Suspicion of VUR and/or pyelonephritis</td>
<td>VCUG and/or DMSA scan.</td>
</tr>
<tr>
<td><strong>Spanish Association of Paediatrics[^36]</strong></td>
<td></td>
</tr>
<tr>
<td>UTI that requires admission, is recurrent or with suspected complications</td>
<td>Inpatient ultrasound.</td>
</tr>
<tr>
<td>First UTI if aged &lt;6 months</td>
<td>Outpatient ultrasound.</td>
</tr>
<tr>
<td>Recurrent or atypical UTI</td>
<td>Outpatient ultrasound, and VCUG or contrast enhanced bladder ultrasound especially if aged &lt;6 months, and DMSA scan especially if aged &lt;3 years.</td>
</tr>
</tbody>
</table>

Uncomplicated UTI: responds well to appropriate treatment within 48 hours.

Atypical UTI: includes very unwell/sepsis, abnormal urine flow or renal function, non-<i>Escherichia coli</i> uropathogen.

Recurrent UTI: ≥3 episodes of cystitis or ≥2 episodes of UTI including at least one episode of pyelonephritis.

Inpatient ultrasound: during acute infection.

Outpatient ultrasound: within 6 weeks.

Outpatient DMSA scan: 4–6 months following UTI to differentiate acute infection from scarring.

NICE, CPS and AAP guidelines suggest consider VCUG if abnormal ultrasound, for example, dilation suggesting severe VUR, obstruction and scarring.

DMSA, dimercaptosuccinic acid; UTI, urinary tract infection; VCUG, voiding cystourethrogram; VUR, vesicoureteric reflux.

### Imaging

Historically, guidelines recommended aggressive imaging follow-up to identify renal scarring and complications from UTI. It is now known that the most children at risk of complications have structural abnormalities identifiable on ultrasound or recurrent UTI. Therefore, many recent guidelines suggest less or no imaging after first uncomplicated UTI for older children and less aggressive imaging after recurrent UTI (table 3).[^24]

### Ultrasound

Ultrasound is non-invasive, relatively inexpensive and an appropriate first-line investigation when imaging is indicated. Ultrasound can detect anatomical abnormalities and hydronephrosis or hydrourter suggesting obstruction or VUR. American and Canadian guidelines recommend ultrasound for all children aged <2 years with first UTI;[^21][^35] European Association of Urology guidelines recommend ultrasound for all children with first febrile UTI,[^23] while NICE recommends ultrasound only for
infants <6 months with first UTI unless infection is atypical or not responding to treatment. The NICE approach reflects the view that routine imaging after all first UTI is not cost-effective; however, imaging in younger children and other selected cases is more likely to detect findings of clinical significance. Ultrasound cannot exclude all cases of VUR but should detect most higher grade and clinically significant cases.

### Dimercaptosuccinic acid (DMSA) scan

DMSA scan is a nuclear isotope uptake scan. Reduced uptake in the kidney can reflect either acute dysfunction (pyelonephritis) or long term damage (scarring), depending on the timing of the test. It is rarely required acutely but may help guide long-term management. DMSA may be indicated if UTI is atypical, recurrent or if initial ultrasound is significantly abnormal.

### Voiding cystourethrogram (VCUG)

VCUG uses fluoroscopy (real-time X-ray) to identify the course of contrast inserted by bladder catheterisation. Bladder filling, emptying and ureteric reflux can be identified. While VCUG is the gold standard for identifying and quantifying VUR, the procedure has a radiation burden and is invasive.

Consensus for exactly who and how to image is lacking. Cost, invasiveness and radiation burden must be balanced against the likelihood of identifying an abnormality which may change management for the child. While most children with uncomplicated UTI outside infancy do not require any imaging, some children are at risk of long-term morbidity after UTI. Therefore, targeted imaging and surveillance strategies for children with selected indications remains appropriate.

### SPECIAL CASES

#### Reflux: a state of flux

Historical approaches assumed VUR could lead to significant long-term renal damage, therefore should be identified early. There is now increasing awareness that much of the renal disease based on reflux is congenital, with an appreciation of mild hydronephrosis and VUR as likely normal physiological states that resolve spontaneously. Given that lower grade reflux is unlikely to cause clinically significant scarring, and mild scarring without other risk factors is unlikely to cause long-term renal dysfunction, aggressive identification of all VUR is unwarranted. Active management strategies should still be considered for higher grade VUR (figure 3).

#### Anatomical abnormalities

Anatomical abnormalities of the renal system can predispose to UTI morbidity but are now often (but not always) detected on routine antenatal ultrasound screening in developed settings. Significant abnormalities warrant appropriate follow-up.

### Recurrent UTI: prophylaxis and prevention

There are few pragmatic strategies to reduce the risk of recurrent UTI in children. Circumcision reduces the risk of UTI in males, but involves surgery, with a number needed to treat of >100 to prevent one UTI. There is insufficient evidence to support cranberry prophylaxis or probiotics. Antibiotic prophylaxis has modest benefits, increases antibiotic resistance and is not indicated after first or second UTI in otherwise healthy children. For children with VUR, antibiotic prophylaxis reduces UTI recurrence but does not reduce scarring. Simple hygiene such as wiping front to back in females can avoid introducing bacteria into the urethral orifice. Active management of toilet training and constipation is important to prevent functional bladder–bowel dysfunction.

### SUMMARY

UTI is a common bacterial infection of childhood. Clinical diagnosis is unreliable, and a urine sample is required for diagnosis, but collection is not straightforward in precontinent children. Dipstick leukocyte and nitrite screening can inform initial management while awaiting culture confirmation. Prompt management aims to prevent short-term morbidity such as urosepsis and long-term morbidity such as renal scarring. Recent evidence supports less aggressive imaging following uncomplicated UTI. Antibiotic resistance is an increasing challenge. International guidelines have conflicting recommendations regarding sample collection methods, antibiotic
duration and imaging indications. Targeted research is required to inform knowledge gaps and inform cost-effective care for paediatric UTI.

Contributors JK drafted the manuscript, which was revised by all authors.

Funding JK is supported in part by an Australian Government Research Training Program Scholarship and Melbourne Children’s Postgraduate Health Research Scholarship.

Competing interests None declared.

Patient consent for publication Not required.

Provenance and peer review Commissioned; externally peer reviewed.

Data availability statement There are no data in this work.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, provided the original work is properly cited, appropriate credit is given, any changes made are indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

REFERENCES


